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STUDY PROTOCOL Open Access
CXCR2 Inhibition – a novel approach to
treating CoronAry heart DiseAse (CICADA):
study protocol for a randomised
controlled trial
Jubin P. Joseph1* , Eliana Reyes2, Josephine Guzman5, Jim O’Doherty2, Hannah McConkey1, Satpal Arri1,
Rahul Kakkar3, Nicholas Beckley4, Abdel Douiri4, Sally F. Barrington2, Simon R. Redwood5 and Albert Ferro6
Abstract
Background: There is emerging evidence of the central role of neutrophils in both atherosclerotic plaque formation
and rupture. Patients with lower neutrophil counts following acute coronary syndromes tend to have a greater
coronary flow reserve, which is a strong predictor of long-term cardiovascular health. But so far, no data are available
regarding the impact of neutrophil inhibition on cardiovascular clinical or surrogate endpoints. Therefore, the aim of
this study is to investigate the effects of AZD5069, a cysteine-X-cysteine chemokine receptor 2 (CXCR2) inhibitor, on
coronary flow reserve and coronary structure and function in patients with coronary artery disease.
Methods/Design: Ninety subjects with coronary artery disease undergoing percutaneous coronary intervention will be
included in this investigator-driven, randomised, placebo-controlled, double-blind, phase IIa, single-centre study.
Participants will be randomised to receive either AZD5069 (40 mg) administered orally twice daily or placebo for
24 weeks. Change in coronary flow reserve as determined by 13N-ammonia positron emission tomography-computed
tomography will be the primary outcome. Change in the inflammatory component of coronary plaque structure and
the backward expansion wave, an invasive coronary physiological measure of diastolic function, will be assessed as
secondary outcomes.
Discussion: Cardiovascular surrogate parameters, such as coronary flow reserve, may provide insights into the
potential mechanisms of the cardiovascular effects of CXCR2 inhibitors. Currently, ongoing trials do not specifically
focus on neutrophil function as a target of intervention, and we therefore believe that our study will contribute to a
better understanding of the role of neutrophil-mediated inflammation in coronary artery disease.
Trial registration: EudraCT, 2016-000775-24. Registered on 22 July 2016.
International Standard Randomised Controlled Trial Number, ISRCTN48328178. Registered on 25 February 2016.
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Background
Atherosclerosis, the principal cause of myocardial infarc-
tion and stroke, is a progressive inflammatory disease
characterised by the accumulation of lipids and fibrous
elements in large arteries [1]. Being an inflammatory dis-
ease, atherosclerosis involves recruitment of leucocytes
(predominantly neutrophils and monocytes) to sites of
vascular injury. Typically, this is triggered by the accu-
mulation of oxidised low-density lipoprotein (LDL)
within the intima, which stimulates endothelial cells
to express an atherosclerotic phenotype and leads to
the adherence of leucocytes on their surface. These
inflammatory cells transmigrate into the intima, where
monocytes proliferate and differentiate into macro-
phages which take up oxidised LDL, forming foam
cells [1].
Atherosclerotic plaques exhibit two major phenotypes:
(1) stable plaques, characterised by a thick fibrous cap
separating a relatively small lipid core from the lumen,
which are associated with a low risk of thrombotic com-
plications; and (2) unstable plaques, characterised by a
large lipid core covered by a thin fibrous cap prone to
rupture and thrombus formation and associated with
a higher risk of thrombotic complications [2, 3].
Leucocytes—in particular neutrophils and monocytes—are
involved both in atherogenesis and in plaque destabilisa-
tion, the latter especially so for neutrophils [4, 5].
Specifically, neutrophils are over-represented in the vascu-
lature of patients with unstable atherosclerotic plaque [4]
and are associated with histologic features of plaque vul-
nerability [5, 6]. In addition to these established structural
changes, a high-fat meal has been shown to elicit a mild
neutrophilia along with endothelial dysfunction [7]. In re-
cent studies, colchicine, a known neutrophil chemotaxis
inhibitor, has been shown to reduce vascular events in pa-
tients with coronary heart disease [8].
The control of migration of neutrophils into coronary
plaque is not fully understood, but it is thought to involve
cysteine-X-cysteine chemokine receptor 2 (CXCR2) [9].
This G protein-coupled receptor binds interleukin-8 (IL-8)
with high affinity together with chemokine (C-X-C motif)
ligands 1, 2, 3 and 5 (CXCL1, CXCL2, CXCL3 and CXCL5,
respectively). CXCR2 is expressed at a high level in
neutrophils and plays a crucial role in mediating neutrophil
migration, such that its inhibition greatly decreases neutro-
phil recruitment to sites of inflammation [10, 11]. In previ-
ous studies, AZD5069, a specific CXCR2 antagonist, was
found to be potent in inhibiting calcium flux, chemotaxis
and CD11b expression on human neutrophils in vitro in
response to the CXCR2 ligands IL-8 and growth related
oncogene-α [12]. In a rodent lipopolysaccharide (LPS)
challenge model of pulmonary inflammation, AZD5069 re-
duced LPS-induced neutrophilia in a dose-dependent man-
ner in both bronchial fluid and serum [13].
Because neutrophil recruitment into atherosclerotic
plaques plays a crucial role in plaque destabilisation and
vascular inflammation, it is possible that CXCR2 inhib-
ition will give rise to improved coronary endothelial
function, which will be reflected in an improvement in
total coronary flow reserve (CFR). CFR is an integrated
measure of coronary artery status encompassing both
macro- and microvascular function, and it has prognos-
tic value over and above other markers of cardiovascular
risk [14]. Therefore, improvement in CFR with CXCR2
inhibition would be expected to translate into prognostic
benefits clinically in long-term follow-up.
In addition to the effects on coronary flow dynamics,
decreased neutrophil recruitment may also translate into a
reduction in the high-risk morphologic features of coron-
ary plaque (visualised by virtual histology intravascular
ultrasound [VH-IVUS] as a diminution in size of the nec-
rotic core of lesions). Additionally, there is evidence that
neutrophil infiltration is involved in the pathophysiology
of restenosis following coronary angioplasty [15, 16].
Therefore, in the CXCR2 Inhibition – a novel ap-
proach to treating CoronAry heart DiseAse (CICADA)
study, we aim to perform a randomised, placebo-
controlled, double-blind trial to investigate the effect of
the CXCR2 inhibitor AZD5069 on CFR and coronary
plaque morphology. This will help to improve under-
standing of the cardiovascular effects of CXCR2 inhib-
ition in patients with coronary artery disease (CAD).
Methods
Design
This is a prospective, randomised, placebo-controlled,
double-blind, phase IIa, single-centre study to evaluate
the effect of the CXCR2 antagonist AZD5069 40 mg
twice daily on cardiovascular surrogate measures in pa-
tients with CAD undergoing percutaneous coronary
intervention (PCI). The trial was approved by the South
Central - Berkshire B Research Ethics Committee
(16/SC/0478) and is to be conducted at the Department
of Cardiology, St. Thomas’ Hospital, London, UK. The
study is co-sponsored by King’s College London and Guy’s
and St. Thomas’ NHS Foundation Trust.
All participants will be asked to provide written informed
consent before entering the study. Clinical trial authorisa-
tion has been obtained from the Medicines and Healthcare
Products Regulatory Agency (MHRA) (EudraCT, 2016-
000775-24). A certificate for the administration of
radioactive medicinal products has been granted by the
UK Administration of Radioactive Substances Advisory
Committee (ARSAC) (RPC 261/3492/35652). Important
protocol modifications will be reported to the South
Central - Berkshire B Research Ethics Committee and, if
necessary, to the MHRA and ARSAC. This study follows
the international recommendations for interventional
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trials (see Fig. 1 and the Standard Protocol Items: Recom-
mendations for Interventional Trials [SPIRIT] checklist in
Additional file 1).
Primary objective
The primary objective of this trial is to determine, in
patients undergoing PCI for atherosclerotic coronary
disease, if 24 weeks of CXCR2 inhibition therapy will
give rise to improvement in CFR as measured by
13N-ammonia positron emission tomography-computed
tomography (PET-CT) compared with placebo.
Secondary objective
The secondary objectives of the study are to ascertain, in
patients undergoing PCI for atherosclerotic coronary
disease, if 24 weeks of CXCR2 inhibition therapy will re-
sult in a reduction in the inflammatory component of
coronary plaque, a decrease in the degree of in-stent
restenosis and improvements in coronary microvascular
function compared with placebo.
Inclusion and exclusion criteria
Participants in the trial will be aged ≥ 18 years, have an-
giographically proven coronary heart disease, be under-
going native-vessel PCI, and have a persistent neutrophil
count > 4.0 × 109/L. Otherwise, they will be receiving the
standard of care for ischaemic heart disease (including
appropriate antiplatelet therapy, statin, and/or antihyper-
tensives as clinically indicated).
The exclusion criteria are as follows: acute ST-elevation
myocardial infarction, prior cardiovascular surgery, known
active or recent infection, evidence of tuberculosis, known
immunocompromised state or history of organ transplant-
ation, known major organ dysfunction or other significant
co-morbidity, use of a cytochrome P450 3A4 inhibitor and
inducers, alanine aminotransferase or aspartate amino-
transferase level ≥ 2.5 times the upper limit of normal,
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure for the CXCR2 Inhibition – a novel approach to treating
CoronAry heart DiseAse (CICADA) trial, outlining schedule for enrolment, intervention and assessments. ECG Electrocardiogram, hs-CRP High-sensitivity
C-reactive protein, MPA Monocyte-platelet aggregates, PET Positron emission tomography
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QTc > 450 milliseconds for males and >470 milliseconds
for females, pregnancy or breastfeeding during the study,
women of childbearing potential not using a highly effect-
ive method of contraception, and unwilling or unable to
give informed consent.
Eligibility and recruitment
The study population will consist of 90 subjects with
CAD undergoing PCI. Subjects are identified from in-
patient admissions and outpatient angioplasty waiting
lists at St. Thomas’ Hospital, London, UK. The direct
care team staff will inform patients about the possibility
of being enrolled in this study. No study-related proce-
dures are undertaken before obtaining informed consent.
A member of the study team will explain the study pro-
cedures in detail and provide the participant with a pa-
tient information sheet. After a minimum of 2 h, but
ideally more than 24 h, the participant will be asked
about their willingness to participate in this research
study, and any questions will be clarified. After informed
consent is obtained, participants will be given a copy of
the informed consent form to sign and assigned a
screening identification number.
Screening
Screening of participants consists of the evaluation of in-
clusion and exclusion criteria. After informed consent is
obtained by a member of the trial team, an electronic
case report form (eCRF) is created for potential partici-
pants, including information about medical history,
physical examination and their current medications.
Women of childbearing potential undergo urine preg-
nancy testing.
Participant timeline
If eligible, subjects are scheduled for the following study
visits (Fig. 1). Patients undergo invasive coronary angiog-
raphy with PCI as per normal clinical care, but they will
also undergo IVUS to provide greyscale and virtual hist-
ology of all major coronary arteries. Patients with suitable
coronary anatomy will be invited to have invasive assess-
ment of coronary and microvascular physiology under
adenosine-induced hyperaemia (using a ComboWire;
Volcano Corp., Rancho Cordova, CA, USA).
Four weeks later, subjects will re-attend the cardiology
department, at which time a full history and physical
examination will be performed and inclusion criteria
confirmed. Assessments will include a 12-lead electro-
cardiogram, as well as blood tests (fasted) for blood
count and biochemistry (renal, liver, lipid, glycaemic and
thyroid profiles) and high-sensitivity C-reactive protein
(hs-CRP) and homocysteine levels. Screening blood tests
for disorders which may exclude patients from the study
will be drawn as indicated (e.g., serum hepatitis B
surface antigen, hepatitis C antibody, and HIV testing if
prompted by history). Additionally, an aliquot of blood
will be taken for measurement of circulating monocyte-
platelet aggregates (MPAs, a highly sensitive and repro-
ducible index of degree of platelet activation) by flow
cytometry. In the case of women of childbearing
potential, pregnancy will be excluded by performing a
pregnancy test on a spot urine. Once eligibility has been
confirmed, 13N-ammonia PET-CT cardiac scans will be
obtained at rest and during adenosine-induced hyper-
aemia to measure CFR. The CT scan will be obtained
prior to the PET scan for attenuation correction at rest
and stress, and prior to the rest scan, the CT scan will
also be used to measure calcium score.
After randomisation, subjects will be allocated 2:1 to
receive either AZD5069 or matched placebo, orally, for
the succeeding 24 weeks. At different time points (weeks
1, 2, 4, 8, 12, 16, 20 and 24), patients will attend for re-
peat visits, at which time they will undergo a physical
examination and have a blood sample taken for the pur-
pose of determining safety and efficacy biomarkers. At
weeks 1, 12 and 24, patients will attend prior to their
morning dose, and additional blood samples will be
taken for the purpose of measuring plasma drug levels.
At weeks 4, 8, 12, 16, 20 and 24, spot urine samples will
be obtained from women of childbearing potential in
order to exclude pregnancy; if they have a positive test
result at any point, they will be immediately withdrawn
from the study. At week 24, a repeat 13N-ammonia PET
scan will be obtained to assess change from baseline in
total CFR, and at the same time point, repeat coronary
angiography together with IVUS will be performed to as-
sess change in plaque composition and degree of resten-
osis. Those patients who initially had a ComboWire
assessment will be invited to have a repeat assessment at
the time of their repeat coronary angiography. A flow
diagram of the protocol is shown in Fig. 2.
Outcome measurements
The primary outcome is the change in total CFR from
baseline, as measured by 13N-ammonia PET, before and
after 24 weeks of treatment with AZD5069 or matched
placebo. The secondary endpoints are as follows:
1. Change in plaque composition, as measured by
VH-IVUS, before and after 24 weeks of treatment
with AZD5069 or matched placebo
2. Degree of in-stent restenosis, as measured by IVUS,
before and after 24 weeks of treatment with
AZD5069 or matched placebo
3. Change in the magnitude of the backward expansion
wave (BEW), as measured by ComboWire
assessment, before and after 24 weeks of treatment
with AZD5069 or matched placebo
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Randomisation and blinding
Participants will be randomised to one of the two study
arms (AZD5069 versus placebo) in a 2:1 ratio in real
time by using the web-based randomisation service pro-
vided by the King’s Clinical Trials Unit. The randomisa-
tion system is programmed to use block randomisation
with randomly selected block sizes. The randomisation
system sends unblinded treatment allocation codes to
the pharmacy department at Guy’s and St. Thomas’
NHS Foundation Trust and the Emergency Scientific
and Medical Services (ESMS).
The pharmacy department will use treatment allocation
to dispense appropriate study medication or matched pla-
cebo. The labels of the study medication display the name
of the trial, the name of the investigational medicinal
product and contact details of the principal investigator.
A 24-h emergency code break and medical informa-
tion service will be provided by ESMS staff, who are not
involved as study investigators. Each randomised subject
will be provided with a card detailing code break tele-
phone numbers and emergency contact details. Subjects
will be requested to carry this card with them at all
times whilst participating in the trial.
Interventions
The subjects will receive either AZD5069 40 mg or
matched placebo tablets administered orally twice daily
for 24 weeks. The drug and placebo are manufactured by
AstraZeneca (London, UK). The drug product is pre-
sented as plain, round, beige, film-coated tablets packaged
in bottles. The tablets contain mannitol, microcrystalline
cellulose, croscarmellose sodium, sodium lauryl sulphate,
Fig. 2 Flowchart of CXCR2 Inhibition – a novel approach to treating CoronAry heart DiseAse (CICADA) trial protocol. Flowchart depicts the study
process and patient visit details for enrolled candidates in the CICADA study. PCI Percutaneous coronary intervention, PET Positron emission
tomography, IVUS Intravascular ultrasound
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sodium stearyl fumarate, polyvinyl alcohol, titanium
dioxide, polyethylene glycol, talc, iron oxide yellow, iron
oxide red and black iron oxide. Matching placebo tablets
are identical in appearance and tasteless. The pharmacy
department at Guy’s and St. Thomas’ NHS Foundation
Trust packs the medication as 2- to 4-week supplies for
study participants and labels the study medication per
current regulatory requirements.
At each visit, pill counts will be conducted to verify
medication adherence. Significant non-adherence is de-
fined as missing 20% or more doses of trial medication
during the treatment period. In the case of study medi-
cation non-compliance, participants will continue to be
followed to their last visit. These data would not be part
of the per-protocol analysis but would form part of an
intention-to-treat analysis.
Any investigational medicinal product, dispensed and
unused or not dispensed, will be disposed of by the
pharmacy department at Guy’s and St. Thomas’ NHS
Foundation Trust. Withdrawal of consent and major
protocol violations will lead to an early study termin-
ation for the subject.
Physical measurements
Anthropometric measurements are performed on each
participant at each study visit. Weight is measured with
the patient standing and then registered after rounding it
to the nearest 500 g. Height is measured using a metric
tape with the patient standing against a wall, and the value
is marked by a ruler placed horizontally on the vertex of
the patient’s head. Blood pressure is taken using an auto-
mated sphygmomanometer after a 5-minute rest in seden-
tary body position. Core temperature is taken using a
tympanic membrane thermometer.
Procedures for assessing coronary flow reserve with PET
Image acquisition
Patients will be asked to abstain from methylxanthine de-
rivatives, including caffeine, for ≥ 24 h before 13N-ammonia
PET scan acquisition. Vasodilator medications such as
nitrate, β-blockers or calcium channel blockers will be
stopped 24 h before PET scan acquisition.
PET imaging will be performed using a Discovery 710
PET-CT scanner (GE Healthcare, Waukesha, WI, USA).
An intravenous bolus injection of 550 MBq of 13N-
ammonia will be given for both stress and rest image
acquisition. A total of 47 transaxial slices will be recon-
structed over an axial FOV of 15 cm. The acquired PET
pixel size is 2.73 × 2.73 × 3.27 mm. A CT scout projection
determines the heart position within the patient, and
low-dose cine CT (100 kV, 10 mA, 0.5 second/rotation,
40-mm collimation, 5.5-second duration) will be used for
attenuation correction of PET data. The PET acquisition
consists of a series of dynamic scans from 0 to 6 minutes
(12 × 10 seconds, 6 × 20 seconds and 2 × 60 seconds)
followed by a single 20-minute gated static scan.
Approximately 30 minutes after completion of rest im-
aging, stress imaging will be performed with adenosine
(140 μg/kg/minute) infused intravenously for at least 3 mi-
nutes before tracer injection. CT-based attenuation cor-
rection will be repeated for the stress study.
Myocardial blood flow and coronary flow reserve
PET images will be reconstructed using an iterative
ordered subsets expectation maximisation algorithm
(2 iterations, 24 subsets), and absolute myocardial blood
flow will be quantified with a commercially available soft-
ware tool (SyngoMBF; Siemens Medical Solutions, Hoffman
Estates, IL, USA). The software automatically determines
the arterial input and myocardial uptake functions and
calculates total and segmental perfusion using the model
of DeGrado et al. [17]. Total and regional CFR of the three
main coronary territories (left anterior descending, left cir-
cumflex and right coronary arteries) will be computed.
The above methodology will be used to assess CFR at
baseline and after 24 weeks of therapy. The CFR is
expected to increase following CXCR2 inhibition as
compared with placebo.
Procedures for assessing coronary restenosis and plaque
composition
Image acquisition
Angiography and IVUS imaging will be performed after
administration of 200 μg of intracoronary nitroglycerine.
Angiography will be performed so that each vessel is
viewed from at least two orthogonal angles after the
planned PCI. For the IVUS procedure, a 45-MHz,
3.2-French, rotational IVUS catheter (Revolution; Volcano
Corp.) will be used. After the IVUS catheter is placed in
the distal vessel, the catheter will be pulled back to the
aortic ostium using the motorised pull-back system at
0.5 cm/second. During pull-back, greyscale IVUS will
be recorded and displayed in real time, and raw radiofre-
quency data will be captured at the top of the R wave
for post-procedural reconstruction of the colour-
coded map by a VH-IVUS data recorder (s5 Imaging
System; Volcano Corp.).
Greyscale and VH-IVUS analyses
The smallest lumen at the area of percutaneous inter-
vention is identified from axial and longitudinal plaque
distribution. At this site, vessel cross‐sectional area
(CSA) will be calculated. The degree of restenosis will be
assessed at 24 weeks by IVUS to measure minimum
luminal CSA. This will be measured during the baseline
PCI and again following 24 weeks of therapy. The degree
of restenosis is expected to be reduced after 24 weeks of
treatment with CXCR2 inhibition.
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Atherosclerotic coronary plaques are characterised by
classification trees on the basis of mathematical autore-
gressive spectral analysis of IVUS back‐scatter data
(echoPlaque 4; INDEC Systems, Los Altos, CA, USA).
Fibrous areas are marked in green, fibrofatty in yellow,
dense calcium in white and necrotic core in red on the re-
constructed colour‐coded tissue map. The area and per-
centage area of each plaque component in the tissue map
are calculated automatically using echoPlaque software.
Measurements are made for the entire length of vessel
that VH-IVUS images are acquired. The volume of ves-
sel and each plaque component is calculated using
Simpson’s method and averaged over the length of the
lesion to also generate a mean plaque area. Plaque com-
position will be assessed at baseline and after 24 weeks
of therapy by IVUS using the Volcano Corp. system to
obtain virtual histology. Each coronary artery will have
the total plaque volume recorded and percentage vol-
umes of fibrous, fibrofatty, necrotic core and calcific tis-
sue. We will assess the change in necrotic core volume
between baseline and after 24 weeks of therapy. The
percentage volume of necrotic core is expected to be re-
duced after 24 weeks of treatment with CXCR2 inhib-
ition as compared with placebo.
Procedures for assessing invasive coronary physiology
indices
Using specialised intracoronary wires (ComboWire)
simultaneous measurements of coronary perfusion pres-
sure and blood flow velocity will be performed that will
provide specific coronary physiological data in addition
to 13N-ammonia PET-determined CFR. With these high-
fidelity measurements, we can estimate coronary flow,
the components of the coronary wave profile and indices
of microvascular function. During the invasive study,
this wire will be placed in the distal coronary artery, and
simultaneous measurements of aortic pressure, distal
coronary pressure and distal coronary blood velocity will
be performed during rest conditions and following
adenosine (140 mg/kg/minute)-induced hyperaemia.
At the end of each study, data will be exported onto
CD-ROMs, and appropriate cardiac cycles will be selected
using custom-made software (Study Manager; Volcano
Corp.). These selected beats will be analysed in another
custom-made software application (Cardiac Waves,
written in MATLAB, Delphi version 2010; Embarcadero
Technologies, San Francisco, CA, USA). The flow and
pressure data for the selected cardiac cycles are ensemble-
averaged, which filters out background noise and allows
identification and exclusion of non-physiological record-
ings. These provide means of average peak velocity (APV;
the average of three to five instantaneous peak coronary
flow velocities), aortic and distal coronary pressures, and
wave intensity analysis (WIA) at each time point. These
parameters will be used in calculations to determine the
following indices:
1. CFR: We will assess APV at rest and following
adenosine stress in the vessel that has undergone
PCI. We can then determine vessel-specific regional
CFR using the formula CFR = APVstress/APVrest.
2. WIA: This is a time-domain method of depicting a
waveform in terms of a succession of multiple small
wavefronts. WIA is invaluable in understanding the
forces driving coronary flow, and a key element of
this, the BEW, has been implicated in a number of
disease processes [18]. We will assess WIA during
conditions of adenosine-induced hyperaemia in all
three vessels. We expect that there will be increased
dominance of the BEW with CXCR2 therapy as
compared with placebo.
3. Microvascular resistance: This is the ratio between
distal coronary arterial pressure (Pd) and coronary
flow. The hyperaemic microvascular resistance
(hMR) is a velocity-based index of microvascular
resistance and is the ratio of Pd to APV during
maximal hyperaemia. It is calculated using the
formula hMR = Pd/APV. Microvascular resistance is
expected to be reduced after 24 weeks of treatment
with CXCR2 inhibition as compared with placebo.
Laboratory measurements
A full blood count will be performed by the haematology
laboratory at St. Thomas’ Hospital. Blood (2 ml) will be
sent in an ethylenediaminetetraacetic acid (EDTA) vacutai-
ner tube to the laboratory within 30 minutes of venesec-
tion. Blood biochemistry (renal, liver, lipid, glycaemic and
thyroid profiles), hs-CRP and homocysteine assays will be
performed by the biochemistry laboratory at St. Thomas’
Hospital. Blood (10 ml) will be sent in a clotted vacutainer
tube to the laboratory within 30 minutes of venesection.
Circulating MPA measurement will be performed in our
research laboratories by flow cytometric analysis of whole
blood (4 ml) collected in sodium citrate (0.3% final concen-
tration). Immediately after venepuncture, blood will be
immunostained with different combinations of peridinin–
chlorophyll-protein complex-conjugated anti-human CD14,
fluorescein isothiocyanate-conjugated anti-human CD16
and allophycocyanin-conjugated anti-human CD42b or
CD62P. Isotype control antibodies will be used as negative
controls. After red cell lysis using fluorescence-activated
cell sorting lysing solution (BD Biosciences, San Jose, CA,
USA), samples will be fixed in 1% paraformaldehyde and
kept at 4 °C until analysed within 48 h by flow cytometry.
At visits 4, 8 and 11, we will measure pre-dose
(trough) and peak (2 h post-dose) AZD5069 plasma con-
centrations in all subjects. Pharmacokinetic assays of
AZD5069 and its major human metabolite AZ13587715
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will be conducted via a contracted vendor (Covance Inc.,
Princeton, NJ, USA) that has created and validated the
LC/MS-based analytical method for assessment of
AZD5069 and AZ13587715 in human plasma preserved
in EDTA and stored between − 10 °C and − 30 °C. The
analytical method will be identical to that used in prior
human studies of AZD5069 [13, 19–21]. At monthly in-
tervals, spot urine samples will be obtained from women
of childbearing potential in order to exclude pregnancy
(Alere hCG Easy; Alere Inc., Waltham, MA, USA).
Emergency code break
A 24-h emergency code break and medical information
will be provided by ESMS. Each randomised subject will
be provided with a card detailing code break telephone
numbers and emergency contact details. Subjects will be
requested to carry this card with them always whilst par-
ticipating in the trial.
Withdrawal of subjects
The study drug must be discontinued if any of the fol-
lowing occur:
 An exclusion criterion is incident during the study.
 Absolute neutrophil count < 1 109/L is noted in two
consecutive samples within 48 h.
 The participant misses > 20% of his or her doses.
 The participant decides he or she no longer wishes
to continue.
 It is recommended by the investigator.
Participants have the right to withdraw from the study
at any time for any reason. The investigator also has the
right to withdraw patients from the study drug in the
event of inter-current illness, adverse events (AEs), ser-
ious adverse events (SAEs), suspected unexpected ser-
ious adverse reactions (SUSARs), protocol violations,
cure, or administrative or other reasons. It is understood
by all concerned that an excessive rate of withdrawals
can render the study un-interpretable; therefore, un-
necessary withdrawal of patients should be avoided.
Should a patient decide to withdraw from the study, all
efforts will be made to report the reason for withdrawal
as thoroughly as possible. Should a patient withdraw
from study drug only, efforts will be made to continue
to obtain follow-up data with the permission of the pa-
tient. Participants who wish to withdraw from trial
medication will be asked to confirm whether they are
still willing to provide the following:
 Trial-specific data at subsequent scheduled visits
 Clinical follow-up data collected as per routine
clinical practice
Reporting procedure for all adverse events
Information on all AEs, serious and non-serious, is col-
lected, documented and reported on the appropriate
eCRFs/SAE reporting forms once informed consent has
been signed, and this will end 14 days after completing the
study medication. The following information is recorded:
 Participant details
 AE description
 Body system code
 Start date of event
 End date of event
 Outcome of event
 Intensity/severity of event
 Study procedure related (i.e., causality/relatedness)
 Investigational Medical Product (IMP) related (i.e.,
causality/relatedness)
 Whether the event is serious
 Follow-up information recorded as necessary
AEs considered to be related to study procedure or
medication as judged by a medically qualified investiga-
tor are followed until resolution or the event is consid-
ered stable. All related AEs that result in a subject’s
withdrawal from the study or present at the end of the
study are followed until a satisfactory resolution occurs.
Reporting procedure for serious adverse events
King’s Health Partners Clinical Trials Office (KHP-CTO)
will have responsibility for pharmacovigilance. All SAEs,
SARs and SUSARs will be reported immediately by the
chief investigator (and certainly no later than 24 h) to
the KHP-CTO in accordance with the current pharma-
covigilance policy. The chief investigator will report
SUSARs to the ethics committee.
Statistics and sample size calculation
Because the trial is randomised and double-blinded, all
blood assays, 13N-ammonia PET scans and invasive coron-
ary assessments will be performed with no knowledge of
subject treatment allocation (AZD5069 or placebo). The
primary outcome is change in total CFR as measured by
13N-ammonia PET. Formal power calculations are prob-
lematic because no data exist to date in humans on the re-
lationship between CXCR2 inhibition and CFR. However,
assuming a medium to large effect size (d = 0.7), α error
probability of 0.05 (two-tailed), power 0.80 and allocation
ratio 2:1 (active drug to placebo), power calculation (using
G*Power 3.1.3 software) indicates that we would need 51
subjects in the active and 25 subjects in the placebo group.
Furthermore, unpublished observational data from
AstraZeneca and the Göteborg Hospital (Göteborg,
Sweden) which relate neutrophil counts in stable CAD
and after myocardial infarction with echocardiographic
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CFR are shown in Table 1. On the basis of these analyses,
we will recruit 60 into the active group and 30 into the
placebo group, firstly to allow for lesser effect sizes and
secondly to allow us to better stratify responses to CXCR2
inhibition on the basis of plasma IMP levels achieved.
A secondary outcome is the change in the magnitude
of the BEW, a key component of the coronary wave pro-
file, with maximal hyperaemia. From previous work, we
expect the magnitude of the BEW to increase 40% with
adenosine induced maximal hyperaemia in patients with
CAD. Unpublished data from the host centre suggest
that in patients without CAD, the BEW can increase a
further 14%. Assuming an α error probability of 0.05
(two-tailed), power 0.80 and allocation ratio 2:1 (active
drug to placebo), power calculation (using G*Power 3.1.3
software) indicates that we would need 26 subjects in the
active and 13 subjects in the placebo group. The BEW
measurement has a standard deviation of 21%, as such we
will need to recruit 57 patients in total to undergo Com-
boWire assessment as part of their invasive protocol.
A full description of the statistical analysis plan is be-
yond the scope of this protocol, and will be published
separately. In summary, the primary analysis will be an
intention to treat analysis. An analysis of covariance
model will be used to obtain an estimate for the mean
difference in total CFR between the two treatment
groups including covariates for baseline CFR. The esti-
mated treatment effect will be reported with 95% confi-
dence intervals and corresponding p value.
Data collection
Electronic case report form
Data are captured in an eCRF which is provided, main-
tained and stored by KHP-CTO in London, UK. The
eCRFs are a component of the custom-designed, trial-
specific database built using the InferMed MACRO ap-
plication, version 4.0 (InferMed/Elsevier, London, UK).
Clinical data for the trial are generated by clinical assess-
ments, diagnostic tests, laboratory tests and interviews with
the patient during study visits. Source data take the form
of patient medical records, hospital records, hospital let-
ters/communications, laboratory reports and so forth.
These data are entered into the MACRO application by re-
search staff at the trial site associated with the CICADA
study. Privacy of the patients is guaranteed; stored data
and materials will be identifiable to the person only by a se-
quentially assigned subject number. The eCRF is designed
in accordance with the requirements of the study protocol
and complies with regulatory requirements. Access to the
eCRF is password-protected, and the password is given
only to site personnel. Data generated throughout the
study are monitored, and the eCRFs are checked against
the subject records for accuracy. Following completion of
the eCRFs, the data are checked electronically for
consistency and plausibility by pre-defined range
checks. If necessary, automatic queries are generated
for questionable data.
Data quality control
The clinical research associate and the investigators
meet frequently to review study progress and procedures
and to discuss any AEs or dropouts. Furthermore, a data
monitoring committee has been established to safeguard
the interests of the trial’s participants and to monitor the
data collected in the trial. The data monitoring commit-
tee will meet prior to the start of the study and 6–12
months after the start of the study. The data monitoring
committee may also meet on an ad hoc basis should the
need arise. The data collection, management, analysis
and interpretation, as well as production of publications,
are independent of the funding bodies and other com-
peting interests. The trial results will be disseminated via
journal publication and conference presentation without
exposing the identity of the trial subjects.
Table 1 Relationship between neutrophil count and coronary flow reserve based on previous studies
Study Neutrophil count Echo-based CFR
(mean ± SE)
CFR increase SD of PET-MPR [22] Patients required
(p < 0.05, 80% power)
Stable CAD cohort
5.8 2.10 ± 0.19 0.36
4.6 2.35 ± 0.12 10.6% 0.36 33
4.2 2.43 ± 0.11 13.5% 0.36 19
Post-MI cohort
5.8 2.45 ± 0.07 0.36
4.6 2.64 ± 0.05 7.2% 0.36 57
4.2 2.70 ± 0.05 9.3% 0.36 33
Abbreviations: CFR Coronary flow reserve, PET Positron emission tomography, MPR Myocardial perfusion reserve, CAD Coronary artery disease, MI Myocardial infarction
The relationship between neutrophil count and echo-based CFR in both stable CAD and post-MI cohorts is shown. This demonstrates that lower neutrophil counts
are associated with higher CFR
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Monitoring
Monitoring is undertaken per good clinical practice
guidelines and the study monitoring plan. The study
monitor is suitably trained, qualified and experienced to
perform this task. Data are evaluated for compliance
with the protocol and accuracy in relation to source doc-
uments. The following data are assessed:
 Written informed consent
 Flowchart filled in for included and excluded subjects
 Trial progress
 Primary and secondary outcome collection
 SAEs
 Drug accountability of the study treatment
Discussion
Atherosclerosis is the primary cause of mortality and
morbidity in the Western world. Its pathophysiology is
not fully understood, but both hyperlipidaemia and in-
flammation represent central pillars to both atherogen-
esis and plaque destabilisation. Recent advances point to
a contributory role of neutrophils during this process,
which offers a novel therapeutic target that could im-
prove outcomes in patients with CAD.
Our study is focused on cardiovascular surrogate pa-
rameters, such as CFR function, which cannot replace
outcome trials but can provide insights into the potential
mechanisms of the cardiovascular effects of CXCR2
inhibition. Moreover, currently ongoing trials are not
specifically focused on modulation of neutrophil activity
as a target of intervention. We therefore believe that our
study will contribute to a better understanding of the
role of neutrophil-mediated inflammation in CAD.
Trial status
Recruitment is ongoing.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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